Article
Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes.
Nature communications - 9 Sept 2024
Farrell Kurt, Humphrey Jack, Chang Timothy, Zhao Yi, Leung Yuk Yee, Kuksa Pavel P, Patil Vishakha, Lee Wan-Ping, Kuzma Amanda B, Valladares Otto, Cantwell Laura B, Wang Hui, Ravi Ashvin, De Sanctis Claudia, Han Natalia, Christie Thomas D, Afzal Robina, Kandoi Shrishtee, Whitney Kristen, Krassner Margaret M, Ressler Hadley, Kim SoongHo, Dangoor Diana, Iida Megan A, Casella Alicia, Walker Ruth H, Nirenberg Melissa J, Renton Alan E, Babrowicz Bergan, Coppola Giovanni, Raj Towfique, Höglinger Günter U, Müller Ulrich, Golbe Lawrence I, Morris Huw R, Hardy John, Revesz Tamas, Warner Tom T, Jaunmuktane Zane, Mok Kin Y, Rademakers Rosa, Dickson Dennis W, Ross Owen A, Wang Li-San, Goate Alison, Schellenberg Gerard, Geschwind Daniel H, Crary John F, Naj Adam
Abstract excerpt
Progressive supranuclear palsy (PSP), a rare Parkinsonian disorder, is characterized by problems with movement, balance, and cognition. PSP differs from Alzheimer's disease (AD) and other diseases, displaying abnormal microtubule-associated protein tau by both neuronal and glial cell pathologies. Genetic contributors may mediate these differences; however, the genetics of PSP remain underexplored. Here we conduct...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.